NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Next-Generation Precision Obesity Models in Drug Development
The article discusses the need for advanced preclinical obesity models to support the development of next-generation anti-obesity drugs, highlighting the limitations of traditional models and the emergence of tiered, gene-edited platforms for improved translational accuracy.
The article focuses on the development of next-generation precision obesity models to close the translational gap in anti-obesity drug development, particularly for complex therapeutics like amylin analogues and gene therapies.
Traditional DIO models overemphasize body weight and food intake while neglecting critical pharmacodynamic dimensions such as body composition, energy homeostasis, insulin sensitivity, and target organ histopathology, contributing to high clinical attrition rates.
Gene-edited models using CRISPR/Cas9 enable precise recapitulation of human obesity-associated genetic mutations (e.g., LEP, LEPR, MC4R), providing platforms for antibody validation and mechanistic studies, shifting from availability to precision matching.
The tiered system includes in vitro cell models (e.g., 3T3-L1 differentiation), gene-edited models (single/multi-gene mutations), diet-induced models (high-fat, high-sugar), and chemically/surgically induced models (hypothalamic injury, ovariectomy).
The system includes DEXA/MRI body composition monitoring, indirect calorimetry, glucose and insulin tolerance tests (GTT/ITT), and histopathological examination.
Protheragen Obesity operates under GLP-compliant quality management, with DIO studies achieving >90% induction success over 8–16 weeks and gene-edited models receiving comprehensive genotyping and integration site analysis.
Pharmaceutical companies and research institutions involved in anti-obesity drug development, particularly those working on next-generation therapeutics.